Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Buxtehude – page 75

1 242 clinical trials in Buxtehude, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Buxtehude at a glance
1 242
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 242 trials in Buxtehude

Open in trial search

Study of Copanlisib with Rituximab and CHOP for Untreated Diffuse Large B-Cell Lymphoma in Patients Aged 18-80

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Obesity

Not recruiting

Study Comparing Retatrutide and Tirzepatide for Weight Loss in Adults with Obesity

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Non-Hodgkin's lymphoma+2

Not recruiting

Study on the Safety and Effectiveness of Brexucabtagene Autoleucel for Children and Teens with Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Brexucabtagene Autoleucel
  • Sponsor:Kite Pharma Inc.

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Study on the Safety and Effectiveness of Mebendazole and Low-Dose Cytarabine for Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Cytarabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Buxtehude

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical trials focusing on moderate to severe atopic dermatitis and plaque psoriasis, evaluating novel treatments including amlitelimab, eblasakimab, and ESK-001. Research aims to assess treatment efficacy and long-term safety profiles.

  • Atopic Dermatitis Studies
  • Psoriasis Research
  • Treatment Response Assessment

Multiple studies examining maintenance therapy and dose optimization in chronic skin conditions.

02 Melanoma Research

Comprehensive studies evaluating advanced melanoma treatments, including adjuvant immunotherapy trials with pembrolizumab and novel combination therapies. Research focuses on both early-stage and metastatic disease.

  • Stage III/IV Melanoma
  • Immunotherapy Combinations
  • Disease-Free Survival

Emphasis on developing more effective treatment strategies for high-risk melanoma patients.

03 Rare Dermatological Conditions

Investigating treatments for chronic urticaria, hidradenitis suppurativa, and bullous pemphigoid. Studies evaluate innovative therapies including remibrutinib and dupilumab for these challenging conditions.

  • Chronic Urticaria Management
  • Autoimmune Skin Disorders
  • Novel Therapeutic Approaches

Focus on improving treatment outcomes for patients with resistant disease forms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.